(Q36772955)

16 August 2017

1 reference

title

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review (English)

1 reference

inflammatory bowel diseases

16 August 2017

main subject

0 references

0 references

1 reference

Javier P Gisbert

1

1 reference

16 August 2017

Yago González-Lama

series ordinal

2

1 reference

16 August 2017

José Maté

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

27 March 2007

1 reference

The American Journal of Gastroenterology

16 August 2017

published in

1 reference

16 August 2017

volume

102

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1518-1527

1 reference

Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Review article: thiopurines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Side effects of azathioprine in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-Mercaptopurine is effective in Crohn's disease without concomitant steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

TPMT in the treatment of inflammatory bowel disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Controlled trial of azathioprine in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-thioguanine--efficacy and safety in chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Drug-induced liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Remission maintenance by tioguanine in chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Reversible cholestasis with bile duct injury following azathioprine therapy. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01187.X

10.1111/J.1572-0241.2007.01187.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference